Multidrug-resistant (MDR) pathogens pose a well-recognized global health threat that
demands effective solutions; the situation is deemed a global priority by the World Health …

Cryptococcosis is an important opportunistic infection and a leading cause of meningitis in
patients with HIV infection. The antifungal pharmacological treatment is limited to …

Fungal infections cause more than 1.5 million deaths a year. Due to emerging antifungal
drug resistance, novel strategies are urgently needed to combat life-threatening fungal …

Fungal organisms are ubiquitous in nature, and progress of modern medicine is creating an
expanding number of severely compromised patients susceptible to a variety of …

Control of fungal pathogens is increasingly problematic due to the limited number of
effective drugs available for antifungal therapy. Conventional antifungal drugs could also …

Immunodepression, whether due to HIV infection or organ transplantation, has increased
human vulnerability to fungal infections. These conditions have created an optimal …

Regular protocols for the isolation of fungal extracellular vesicles (EVs) are time-consuming,
hard to reproduce, and produce low yields. In an attempt to improve the protocols used for …

Amphotericin B (AmB) is the antifungal with the strongest fungicidal activity, but its use has
several limitations, mainly associated with its toxicity. Although some lipidic and liposomal …

Fungal infections are a major public health problem resulting from the lack of public policies
addressing these diseases, toxic and/or expensive therapeutic tools, scarce diagnostic tests …

There is a consensus that the antifungal repertoire for the treatment of cryptococcal
infections is limited. Standard treatment involves the administration of an antifungal drug …